The ways in which we treat diseases are becoming more and more innovative, with the biotech industry demonstrating its full potential in the development of new ways to treat patients.

Our industry is constantly inventing, validating, and developing new drug modalities such as antibody-drug conjugates, RNA therapeutics, targeted degradation, gene editing, oligonucleotides and various combinations of these and other tools to address pathophysiological conditions.

Collaboration among industry, academia, regulatory, clinician and patient communities, as well as ad hoc funding and investment frameworks are essential to bring these solutions to the patients.

This year Annual Conference presented some of these biotechnology-driven new therapeutical approaches and partnership models for successful drug development.